Ebner C, Siemann U, Bohle B, Willheim M, Wiedermann U, Schenk S, Klotz F, Ebner H, Kraft D, Scheiner O
Institute of General and Experimental Pathology, University of Vienna, Austria.
Clin Exp Allergy. 1997 Sep;27(9):1007-15. doi: 10.1111/j.1365-2222.1997.tb01252.x.
The mechanisms operative in specific immunotherapy (SIT) of Type I allergy are not completely understood. In the present study we evaluated immunological changes during SIT in pollinosis.
Eight patients suffering from pollinosis (monosensitized to grass pollen) were treated with conventional SIT. All subjects had IgE specific for Phl p 1, a major allergen of timothy grass. In vitro changes in the immunological reactivity to grass pollen extract and to recombinant Phl p 1 were evaluated. Subjects were examined at three occasions: before, after 3 months and after 1 year of SIT.
Serological analysis revealed a marked increase of grass pollen- and Phl p 1-specific IgG, titres of specific IgE did not change significantly. Lymphoproliferative responses to grass pollen extract and rPhl p 1 were reduced already after 3 months of treatment. Accordingly, the cloning efficiency for Phl p 1-specific T-cell clones (TCC) dropped markedly in all patients. The majority of allergen-specific TCC raised before SIT revealed a TH2-like pattern of cytokine production, TCC established after SIT revealed TH1 characteristics. This shift was due to a decrease in IL-4 rather than an increase in IFN-production by T cells. Investigations of the epitopes recognized by T cells before and after SIT did not reveal the outgrowth of new ('protecting') specificities. We could not observe induction of allergen-specific CD8+ lymphocytes (supressor cells).
Our data indicate that -- on the level of TH lymphocytes -- SIT induces tolerance to the allergen and a modulation of the cytokine pattern produced in response to allergen stimulation.
Ⅰ型过敏特异性免疫疗法(SIT)的作用机制尚未完全明确。在本研究中,我们评估了花粉症患者进行SIT期间的免疫变化。
8例花粉症患者(仅对禾本科花粉过敏)接受了传统的SIT治疗。所有受试者均有针对梯牧草主要变应原Phl p 1的特异性IgE。评估了对禾本科花粉提取物和重组Phl p 1免疫反应性的体外变化。在三个时间点对受试者进行检查:SIT前、3个月后和1年后。
血清学分析显示,禾本科花粉和Phl p 1特异性IgG显著增加,特异性IgE滴度无明显变化。治疗3个月后,对禾本科花粉提取物和rPhl p 1的淋巴细胞增殖反应就已降低。相应地,所有患者中Phl p 1特异性T细胞克隆(TCC)的克隆效率显著下降。大多数在SIT前产生的变应原特异性TCC显示出TH2样细胞因子产生模式,而SIT后产生的TCC显示出TH1特征。这种转变是由于T细胞产生的IL-4减少,而非IFN增加所致。对SIT前后T细胞识别的表位进行研究,未发现新的(“保护性”)特异性出现。我们未观察到变应原特异性CD8 +淋巴细胞(抑制细胞)的诱导。
我们的数据表明,在TH淋巴细胞水平上,SIT诱导对变应原的耐受性以及对变应原刺激产生的细胞因子模式进行调节。